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ABSTRACT This study evaluated the effectiveness and usefulness of vaccination against diphtheria 
and tetanus in different age groups in Gaza, Palestine. Blood samples were collected from 180 children 
aged < 12 years, 90 males and 90 females. Using ELISA methods, the efficacy of vaccination was 
estimated at 87.8% for diphtheria and 98.3% for tetanus. Mean serum titres varied significantly by age 
group: for diphtheria 0.24 IU/mL at age 2–4 years, 0.63 IU/mL at 7–8 years and 0.46 IU/mL at 11–12 
years, and for tetanus 1.01 IU/mL, 2.63 IU/mL and 1.20 IU/mL respectively. The relatively low antibody 
titres, especially for diphtheria, suggest the need for a booster dose.
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Efficacité de la vaccination contre la diphtérie et le tétanos à Gaza (Palestine) 
RÉSUMÉ Cette étude a évalué l’efficacité et l’utilité de la vaccination contre la diphtérie et le 
tétanos dans différents groupes d’âge à Gaza (Palestine). Des prélèvements sanguins ont été effectués 
chez 180 enfants âgés de moins de 12 ans (90 garçons et 90 filles). Les techniques ELISA utilisées 
ont permis d’estimer à 87,8 % l’efficacité de la vaccination contre la diphtérie et à 98,3 % celle contre 
le tétanos. Les taux d’anticorps sériques moyens variaient significativement selon le groupe d’âge : 
pour la diphtérie, ils étaient de 0,24 UI/mL de 2 à 4 ans, 0,63 UI/mL de 7 à 8 ans et 0,46 UI/mL de 11 à 
12 ans ; et pour le tétanos, respectivement 1,01 UI/mL, 2,63 UI/mL et 1,20 UI/mL. Les taux d’anticorps 
relativement faibles, notamment pour la diphtérie, semblent indiquer qu’il est nécessaire d’administrer 
une dose de rappel.
الية التلقيح ضد اخُلناق والُكزاز يف غزة بفلسطني فعَّ
ابتسام حسن األسود، حممد عيد شبري 
]التيتانوس[ يف  ]الدفرتيا[ والُكزاز  اخُلناق  التلقيح ضد  فعالية وفائدة  الدراسة  الباحثان يف هذه  يقيِّم  اخلالصـة: 
جمموعات عمرية خمتلفة يف غزة بفلسطني. وقد ُأخذت عيِّنات الدم من 180 طفاًل تقل أعامرهم عن 12 عامًا، منهم 
باإلنزيم(  املرتبط  املناعي  املمتز  )مقايسة  إليزا  طرق  باستخدام  اللقاح  نجاعة  الباحثان  ر  وقدَّ أنثى  و90  ذكرًا   90
ضمن  إحصائيًا  به  يعتّد  تفاوتًا  املصلية  الوسطية  العيارات  تفاوتت  وقد  للُكزاز.  و%98.3  للُخناق   %78.7 بنسبة 
املجموعات العمرية فبلغت بالنسبة للخناق 0.24 وحدة دولية/مل بأعامر 2 – 4 سنوات و0.63 وحدة دولية بعمر 
7 – 8 سنوات و0.46 وحدة دولية/مل بعمر 11 – 12 سنة،كام بلغت بالنسبة للُكزاز 1.01 وحدة دولية/مل لعمر 
2 – 4 سنوات و2.63 وحدة دولية لعمر 7 – 8 سنوات و1.20 وحدة دولية/مل بعمر 11 – 12 سنة. وتدل العيارات 
زة. املنخفضة نسبيًا لألضداد، والسيَّام ألضداد اخلناق عىل احلاجة إىل جرعة معزِّ
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Introduction
Although diphtheria and tetanus occur rare-
ly in the world, outbreaks of diphtheria 
in the former Soviet Union and in several 
Eastern European countries are a remind-
er that even a well-controlled infection 
can re-emerge when herd immunity is not 
maintained [1]. The epidemic in 1990–93 
affected all 15 Newly Independent States, 
and more than 157 000 cases and more than 
5000 deaths were reported [2]. A large pro-
portion of adults in many countries are now 
susceptible to diphtheria. Vaccine-induced 
immunity wanes over time unless a periodic 
booster is given or exposure to toxigenic 
Corynebacterium diphtheriae occurs. The 
immunity gap in adults coupled with large 
numbers of susceptible children creates the 
potential for new extensive epidemics [1].
There are few available studies to evalu-
ate the diphtheria and tetanus vaccination 
programme in Gaza or neighbouring coun-
tries. Swartz et al. studied the immune 
response to diphtheria and tetanus toxoid 
components of a combined diphtheria teta-
nus whole-cell pertussis/enhanced inacti-
vated poliovirus vaccine, administered in a 
3-dose schedule to Israeli infants at 2, 3.5 
and 10 months of age and followed by a 
booster dose at the age of 8 years [3]. This 
was compared with the immune profile of a 
group of children at the same age given the 
customary schedule of diphtheria, pertussis 
and tetanus (DTP) triple-vaccine at 2, 4, 6 
and 12 months of age and a booster at age 8 
years (control group). 
In Gaza the 4 essential doses of the DTP 
triple-vaccine are given at 2, 4, 6 and 12 
months of age, and the DT booster dose is 
given at school entry, age 6 or 7 years. Our 
study aimed to assess the efficacy of diph-
theria and tetanus vaccines in children aged 
2–12 years to evaluate the immunogenicity 
of the booster dose and to follow up the 
duration of immunity by measuring the 
antibody titres in later years and comparing 
them with the approved level for protection 
against these diseases
Methods
This study was conducted from the end of 
May 2005 to the end of July 2005. 
Sample
The study sample was 180 apparently 
healthy children from 3 age groups (2–4 
years 7–8 years and 11–12 years) who had 
received the 3 primary doses of DPT vac-
cine and the 4th booster dose. The last 2 
groups had received the DT booster dose 
at school entry (6 or 7 years). There were 
30 males and 30 females in each group. 
Children aged 2–4 years old were randomly 
chosen from the reception department of Al 
Naser hospital, where they were attending 
for problems other than vaccination, while 
those aged 7–8 years and 11–12 years were 
chosen from 4 primary schools in Gaza. 
Both the schools and the children from them 
were randomly selected. The total number 
of students in each school was 500–600 
and from this number we randomly selected 
40–50 students from different age groups 
until we reach the required number.
The vaccination status for each child 
was checked from records of the Depart-
ment of Health. Children were excluded if 
they had a major congenital defect or seri-
ous chronic illness, had any confirmed or 
suspected immunosuppressive or immuno-
deficiency condition, or were in receipt of 
immunoglobulin or blood product therapy. 
The percentage of DPT vaccine coverage 
in 2002 was 100% for the 3 primary doses 
and 99.3% for the booster dose according to 
the annual report of the Palestinian Ministry 
of Health [4]. 
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Data collection
Blood samples were collected from each 
child in a special room in each school with 
the help of the Directorate of School Health. 
This study was conducted according to the 
good clinical practice guidelines and the 
declaration of the Helsinki Health Research 
Committee and the Palestinian Ministry of 
Education. Sample collection was conduct-
ed under the supervision of the Directorate 
of School Health and Al Naser Hospital 
nursing staff. Before enrolment, the purpose 
of the study was explained to the child’s 
parents, and then written informed consent 
was obtained from the parent of every child. 
Participation rate was high (99.5%).
Laboratory methods
A volume of 3–4 mL of blood was drawn 
by venepuncture under aseptic conditions 
and serum was separated by centrifugation. 
Each sample was distributed into 3 tubes 
and then stored at – 80 ºC until the time of 
serological assay.
Antibody titres for diphtheria and teta-
nus were determined by enzyme-liked im-
munosorbent assay (ELISA) techniques, 
which were performed according to the 
manufacturer’s instructions. Two reagents 
were used in the study: the ELISA kit for 
diphtheria anti toxoid (Adaltis Italia SpA) 
and the ELISA kit for tetanus antitoxoid 
(Adaltis Italia SpA). Readings were made 
using an ELISA reader (TC 89+). Accord-
ing to World Health Organization (WHO) 
standards, we defined the protective level 
for both diphtheria and tetanus antibodies 
as 0.1 IU/mL [5,6].
The DPT and DT vaccines used in Pales-
tinian vaccination centres are manufactured 
by Aventis Pasteur and are approved by 
WHO. 
Data analysis
Data were coded numerically, entered into 
SPSS, version 8.0 and sorted according to 
sex and age. The arithmetic mean of an-
tibody titres was calculated for each age 
group and statistical significance was ana-
lysed using 1-way analysis of variance 
(ANOVA). The percentage of children who 
had antibody titres < 0.1 IU/mL and ≥ 0.1 
IU/mL was calculated, and statistical sig-
nificance in vaccination efficacy among 
age groups and between males and females 
were analysed using the chi-squared test.
Results 
Diphtheria 
The results showed that overall 87.8% of 
children below 12 years old were well im-
munized against diphtheria and had a protec-
tive level of diphtheria antibody (≥ 0.1 IU/
mL). The proportion of children who were 
protected against diphtheria was 83.3% 
among the children aged 2–4 years, 95.0% 
for the group 7–8 years and 85.0% for the 
group aged 11–12 years (Table 1). There 
was also a significant difference of protec-
tion against diphtheria after the DT booster 
dose given at 6 years old (P = 0.040). The 
efficacy of diphtheria vaccine not signifi-
cantly different between the sexes (83.3% 
in boys and 92.2% in girls, P = 0.069) (Ta-
ble 2). 
Table 3 shows that the overall mean 
diphtheria antibody titre was 0.44 IU/mL 
(0.24 IU/mL, 0.63 IU/mL and 0.46 IU/mL 
in the 3 age groups respectively). There 
were significant difference between the 2–4 
years and 7–8 years age groups (P < 0.001), 
the 11–12 years and 7–8 years age groups 
(P = 0.003), and the 2–4 years and 11–12 
years age groups (P < 0.001).
Figure 1 shows the distribution of indi-
vidual values in each age group.
Tetanus
Table 1 shows that overall 98.3% of chil-
dren had a protective level of tetanus an-
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Antibody titre < 0.1 (IU/mL)
(not protected)
Antibody titre ≥ 0.1 (IU/mL) 
(protected)
DT TT DT TT
No. % No. % No. % No. %
2–4 60 10 16.7 0 0.0 50 83.3 60 100.0
7–8 60 3 5.0 0 0.0 57 95.0 60 100.0
11–12 60 9 15.0 3 5.0 51 85.0 57 95.0
Total 180 22 12.2 3 1.7 158 87.8 177 98.3
For DT χ2 = 4.45, df = 2, P = 0.108; for TT χ2 = 6.102, df = 2, P = 0.04. 
Table 2 Protection against diphtheria (DT) and tetanus (TT) among children by sex
Sex No. of 
children
Antibody titre < 0.1 (IU/mL)
(not protected)
Antibody titre ≥ 0.1 (IU/mL) 
(protected)
DT TT DT TT
No. % No. % No. % No. %
Male 90 15 16.7 2 2.2 75 83.3 88 97.8
Female 90 7 7.8 1 1.1 83 92.2 89 98.9
Total 180 22 12.2 3 1.7 158 87.8 177 98.3
For DT χ2 = 3.314, df = 1, P = 0.069; for TT χ2 = 0.339, df = 1, P = 0.56.
tibody (≥ 0.1 IU/mL). All children in age 
groups 2–4 and 7–8 years were protected 
against tetanus and 95.0% in age group 
11–12 years were protected. Tetanus vac-
cine efficacy also showed no difference by 
sex (97.8% in boys and 98.9% in girls, P 
= 0.56) (Table 2). 
Table 3 shows that the overall mean 
tetanus antibody titres was 1.61 IU/mL 
(1.01 IU/mL, 2.63 IU/mL and 1.20 IU/mL 
in the 3 age groups respectively). There was 
a significant difference between the 2–4 
years and 7–8 years age groups (P < 0.001), 
and between the 11–12 years and 7–8 years 
age groups (P < 0.001), but not between the 
2–4 years and 11–12 years age groups (P 
= 0.498).
Figure 2 shows the distribution of indi-
vidual values in each age group.
Discussion
This study focused on the humoral immune 
response to diphtheria and tetanus toxoid 
vaccines in the sera of children below 12 
years old. This was accomplished by meas-
uring antibody titres for these toxoids and 
Table 3 Mean diphtheria (DT) and tetanus (TT) antibody titres among children by age and sex
Sex No. of 
children
Mean antibody titre (IU/mL)
Age 2–4 years Age 7–8 years Age 11–12 years Total
DT TT DT TT DT TT DT TT
Male 90 0.22 0.90 0.72 3.23 0.45 1.15 0.46 1.76
Female 90 0.26 1.11 0.55 2.02 0.47 1.26 0.43 1.46
Total 180 0.24 1.01 0.63 2.63 0.46 1.20 0.44 1.61
Eastern Mediterranean Health Journal, Vol. 15, No. 2, 2009 289
املجلة الصحية لرشق املتوسط، منظمة الصحة العاملية، املجلد اخلامس عرش، العدد ٢، ٢٠٠9 
Figure 1 Distribution of individual values for diphtheria toxoid antibody titre among children in 
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Figure 2 Distribution of individual values for tetanus toxoid antibody titre among children in the 
different age groups (a) 2–4 years, (b) 7–8 years, (c) 11–12 years
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comparing them with the minimum protec-
tive level recommended by WHO for in 
vitro measurement of both diphtheria and 
tetanus antitoxoids (0.1 IU/mL) [5,6]. The 
percentage of children who had titres above 
and below the protective level was calcu-
lated for each age group. 
Although diphtheria and tetanus are now 
rare diseases in Gaza, and no cases have 
been reported for several years, analysis of 
serum specimens from children aged under 
12 years demonstrated that a considerable 
proportion of them lack protective levels 
for diphtheria antibodies. Although DPT 
vaccine has a high reported coverage in 
Gaza—100% for the 3 primary doses and 
99.3% for the booster dose [4]—12.2% of 
children in our sample were not protected 
against diphtheria and 1.7% were not pro-
tected against tetanus. This raises concern 
that in an outbreak of diphtheria many 
people would be at-risk.
Our finding of 87.8% of children in the 
different age groups with diphtheria anti-
toxoid level ≥ 0.1 IU/mL is lower than the 
efficacy obtained by McQuillan et al. in the 
United States, where 91% of children aged 
6–11 years old were protected against diph-
theria [7]. Carlsson et al. found 89% of 5.5-
year-old Swedish children were protected, 
a relatively high percentage, despite the fact 
that those children received only 1 booster 
dose [8]. Mark et al.’s study of children aged 
6, 10 and 16 years old in Sweden revealed 
that 15%, 48% and 24% respectively were 
not protected against diphtheria (antibody 
titres < 0.01 IU/mL) [9]. Their efficacy was 
low compared with our study. 
The efficacy level in our study is also 
higher than Slusarczyk et al. who studied 
the immunity of children aged 6–8 years 
against pertussis, tetanus and diphtheria in 
Poland. Protective levels were detected in 
70%, 58% and 45% of children aged 6, 7 and 
8 years respectively [10]. This percentage is 
low due to the absence of a booster dose at 
school entry. Lagergård et al. in Sweden 
determined the neutralizing antibodies and 
specific immunoglobulin isotype levels in 
infants after vaccination against diphtheria 
[11]. Between 6–30 months of age all chil-
dren were protected, whereas at 30 months 
only 48% remained protected. This result 
is much lower than the results obtained in 
our study. 
While the efficacy of tetanus vacci-
nation in our study was high—98.3% of 
children in the different age groups had 
antitoxoid level ≥ 0.1 IU/mL and only 1.7% 
of children were not protected—this level 
is in agreement with McQuillan et al. who 
found that 91% of children aged 6–11 years 
were protected against tetanus [7]. It also 
agreed with Aboud et al. who determined 
the serological response in children aged 
1–15 years immunized with DPT vaccine 
alone or with a tetanus toxoid booster dose 
in Tanzania [12]. The percentage of pro-
tected children was 94.7% and 98.0% at age 
1–5 years and 53.3% and 55% at age 6–15 
years in Dar es Salaam and Bagamoyo, Tan-
zania respectively. Carlsson et al. found that 
93% of the subjects were protected against 
tetanus [8]. Lower results were obtained by 
Viviani et al. who evaluated the expanded 
programme for immunization in The Gam-
bia, and found protective antibody levels in 
87% of 8–9 year-olds versus 95% of 3–4 
year-olds [13]. Slusarczyk et al. found that 
protective tetanus levels were 70%, 58% 
and 45% of children aged 6, 7 and 8 years 
respectively [10].
The level of antibody titres declines 
before the administration of the booster 
dose and may continue to decrease below 
the protective level. This agrees with results 
obtained for diphtheria which indicates 
that vaccine does not provide individu-
als with long-term protection. In Schou et 
al.’s study in Denmark the mean diphtheria 
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antibody titre (4.1 IU/mL) was higher than 
in ours (0.44 IU/mL) [14]. In the study of 
Björkhom et al. in Sweden the booster dose 
elevated the mean titre from 0.03 IU/mL to 
1.18 IU/mL [15], and in the study of Aboud 
the mean titre for tetanus antitoxoid was 
0.82 IU/mL for age group 1–5 years, 0.13 
IU/mL for 6–10 years and 0.45 IU/mL for 
11–15 years after a booster dose given at 
10 years. That study classified participants 
according to the time after vaccination; in 
those who received the last dose at ≤ 4 years 
the titre was 0.87 IU/mL and for those aged 
4–9 years the titre was 0.29 IU/mL [12]. 
The efficacy of diphtheria and tetanus 
vaccine varies from one research study to 
another, and differences in these results 
may be due to several reasons. First, there is 
the modifying effect of passively-acquired 
maternal antibodies in young infants which 
could suppress the development of active 
immunity following early administration of 
DPT vaccine. The interference is accentu-
ated in infants who have cord serum titres 
above 0.1 IU/mL [5,6]. 
The endemicity of diphtheria is another 
reason explaining the variability of results 
among various studies. In developing coun-
tries, a high rate of skin infections caused by 
C. diphtheriae creates a primary reservoir of 
diphtheria organisms. This appears to be an 
important factor in the early development of 
natural immunity against the disease. 
Socioeconomic and sociocultural 
changes, including improved hygiene and 
different lifestyles, may also change the 
epidemiological patterns of diphtheria [16]. 
Natural immunity against tetanus is one 
of the most important factors that affect 
vaccine efficacy; it has been proposed that 
natural immunity against tetanus can be in-
duced by a sublethal dose of tetanus toxin or 
by fragments of tetanus toxin released from 
tetanus bacilli located in the digestive tract, 
as a result of ingesting tetanus spores [17]. 
Some authors report finding tetanus anti-
toxin in the sera of persons who were not 
immunized. Tetanus toxin can be adsorbed 
from the gastrointestinal tract [6]. 
Furthermore, studies have demonstrated 
that administration of vaccine doses at in-
tervals less than the recommended minimal 
intervals or earlier than the minimal ages 
may interfere with antibody response and 
protection, while increasing the interval be-
tween doses of a multidose vaccine does not 
diminish the effectiveness of the vaccine 
[18]. The 4th dose in the Gaza schedule is 
given at 12 months, which is the minimum 
age recommended. Increasing this age to 15 
or 18 months would increase the interval 
between this dose and the previous one, and 
enhance better immune response. 
Storage and distribution of vaccines 
also affects the validity of the vaccine; all 
vaccines are sensitive biological substances 
and lose their potency with time [19]. Tak-
ing into consideration that the electricity 
supply in Gaza is frequently disconnected, 
this may explain in part the relatively low 
efficacy of diphtheria vaccine. 
Conclusions
• The efficacy of tetanus vaccination 
among children < 12 years in Gaza is 
very high (98.3%), while that of diphthe-
ria was a little lower (87.8%). However, 
relatively low antibody titres were found 
after vaccination, which means that vac-
cine may not give a long-term protection. 
Hence, it is advisable to give the first 
booster dose at 15–18 months instead 
of 12 months in order to increase the 
response to the booster dose and prolong 
its duration. Close monitoring of the 
cold-chain preservation is necessary. 
• The DT booster dose which is given at 
the school entry age is highly immuno-
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genic and raises both vaccine efficacy 
and antibody titres. The significant dif-
ference in both efficacy and antibody ti-
tres in both diphtheria and tetanus before 
and after the reinforcing dose empha-
sizes the need for such a booster. 
• Vaccination efficacy and antibody lev-
els in older children is lower than the 
younger ones, as seen clearly from the 
significant difference between the last 
2 age groups. Hence, it is necessary to 
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Increasing health literacy in semi-literate to illiterate low income 
women
Increasing health literacy in semi-literate to illiterate low income 
women is a part of Item 3 of the EMRO gender and health activities 
“Increasing the productive involvement of women and girls in society 
for maximizing health outcomes” (URL: http://www.emro.who.int/ghd/
activities_womeninvolvement.htm). 
Health literacy is recognized as a necessary component to increase 
positive health outcomes. It reflects the capacity to access and under-
stand basic health information and services and to use that capacity 
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